A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Albert Schömig, Alban Dibra, Stephan Windecker, Julinda Mehilli, José Suárez de Lezo, Christoph Kaiser, Seung Jung Park, Jean Jacque Goy, Jae Hwan Lee, Emilio Di Lorenzo, Jinjin Wu, Peter Jüni, Matthias E. Pfisterer, Bernhard Meier, Adnan Kastrati

Research output: Contribution to journalArticlepeer-review

301 Scopus citations

Abstract

Objectives: Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-eluting stents (DES)-sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)-in patients with coronary artery disease. Background: It is not known whether there are differences in late outcomes between the 2 most commonly used DES: SES and PES. Methods: Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37 months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI). Results: No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p < 0.001) and stent thrombosis (HR 0.66; 95% CI 0.46 to 0.94, p = 0.02) without significantly impacting on the risk of death (HR 0.92; 95% CI 0.74 to 1.13, p = 0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p = 0.10). Conclusions: Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.

Original languageEnglish
Pages (from-to)1373-1380
Number of pages8
JournalJournal of the American College of Cardiology
Volume50
Issue number14
DOIs
StatePublished - 1 Oct 2007

Fingerprint

Dive into the research topics of 'A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease'. Together they form a unique fingerprint.

Cite this